Premium
Downregulation of PTPN 18 can inhibit proliferation and metastasis and promote apoptosis of endometrial cancer
Author(s) -
Cai Junhong,
Huang Sizhe,
Yi Yuping,
Bao Shan
Publication year - 2019
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13098
Subject(s) - endometrial cancer , metastasis , cancer research , cancer , apoptosis , downregulation and upregulation , gene knockdown , gene silencing , cell growth , carcinoma , flow cytometry , immunohistochemistry , medicine , biology , oncology , immunology , biochemistry , gene , genetics
Abstract Endometrial cancer is one of the chief culprits threatening women's lives. Although numerous epidemiological experiments have been carried out into the aetiology of endometrial cancer, the cause of the disease has been unclear up to now. In recent years, PTPN 18, a member of the protein tyrosine phosphatases (PTP) family predicted to be tumour suppressors or oncogenes, has been confirmed to participate in the occurrence and progression of many cancers. Few studies, however, have explained the role in the endometrial cancer. So, it caught our attention to explore if PTPN 18 participates in and plays a regulatory role in the proliferation, apoptosis, and metastasis of endometrial cancer. In our results, we found that PTPN 18 was overexpressed in endometrial cancer tissue compared to paracancerous tissue by immunohistochemistry. Not only that, silencing of PTPN 18 in endometrial cancer cell lines ( HEC ‐1‐A and HEC ‐1‐B) can significantly impair proliferation detected by CCK 8 assay and flow cytometry ( FCM ) analyses and inhibit the metastasis of endometrial cancer cells shown by the scratch test and the Transwell experiment. PTPN 18 knockdown can promote the apoptosis of endometrial cancer. In addition, nude mice tumour formation assay confirmed the results in vivo. Although the exact function of PTPN 18 in endometrial cancer is unclear, the targeted therapy drugs enhancing PTPN 18 may be considered in the future treatment of endometrial carcinoma.